Home › Companies › LGVN

Longeveron

Market cap $7.1M 3.4M shares (vendor count, Nov 18, 2026) × $2.11 close Nov 17, 2026 · share count from the market-data vendor, not the SEC cover page

Catalyst timeline

4 trackedQuarter catalyst calendar →
  1. Laromestrocel DCM Ph2/3 start2H 2026Laromestrocel DCM Ph2/3 start, 2H 2026, routine
  2. Company strategic review4Q 2026Company strategic review, 4Q 2026, routine
  3. Laromestrocel HLHS BLA filing2027Laromestrocel HLHS BLA filing, 2027, material
  4. Pediatric DCM Phase 2 registrational2027Pediatric DCM Phase 2 registrational, 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (3 active programs)

Discontinued (1)

Capital (as filed)

Cash
$7.2M cash and cash equivalents · Sep 30, 2026 (10-Q)
Operating cash flow
−$2.7M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$7.2M cash, runway into the first quarter of 2027 per the update of Nov 12, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (15)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (15 calls)

Every verdict Biotech Distilled has published on Longeveron, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Longeveron Inc (LGVN): Scientific Deep Dive for Lead and Pipeline Products The HLHS science is intriguing but the dilution gap — cash runway ending Q1 2026 while the pivotal data readout is Q3 2026 — is a structural barrier to entry; wait for the inevitable financing to clear before re-evaluating.
  2. Watch UPDATE: Longeveron (LGVN) - Regulatory Momentum & Manufacturing Moat FDA Type C meeting and Japan patent strengthen the regulatory and manufacturing story, but the balance sheet risk remains the gatekeeper; continue to wait for the Q1 2026 financing to clear.
  3. Watch UPDATE : Longeveron (LGVN) - Rare Pediatric Disease PRV Program Reauthorized PRV program reauthorization through 2029 secures the $150M+ voucher optionality, but the dilution gap remains the primary risk; still waiting for the capital raise to clear before entering.
  4. Watch UPDATE: Longeveron (LVGN) - The Financial Fire Alarm is Ringing The 8-K confirming 50% pay cuts, furloughs, and institutional capitulation validates the acute cash crisis; stay on the sidelines and let the dilutive financing event happen before evaluating entry.
  5. Watch UPDATE: Longeveron (LGVN) - Scientific Validation vs. Financial Reality The Cell Stem Cell frailty publication is scientific validation but not a buy signal; it reads as a pre-financing stock-support maneuver, and the dilution gap remains the primary focus.
  6. Watch UPDATE: Longeveron (LGVN) - The Reverse Stock Split and the Dilution Trap The reverse split proxy reveals the mechanism for massive upcoming dilution; the company is actively negotiating financing now, so stay on the sidelines until the deal is announced and the dust settles.
  7. Speculative buy speculative UPDATE: Longeveron (LGVN) - Surviving the Gap (But Pawning the Crown Jewel) The $15M private placement removes near-term bankruptcy risk and funds the company to the Q3 2026 ELPIS II readout, making a run-up trade active, though the diluted cap table and pawned PRV upside lower the ceiling materially.
  8. Speculative buy speculative UPDATE: Longeveron (LGVN) - The 10-K Autopsy The 10-K confirms the cash crunch narrative and the punishing financing terms, but the Coastland/Janus deal extended runway into Q4 2026; hold for the pre-data run-up with disciplined exit targets given diluted cap table and forfeited PRV upside.
  9. Avoid UPDATE: Longeveron (LGVN) - The FDA Pulls the Pivotal Rug The FDA's Type C meeting revoked ELPIS II's pivotal status, struck RVEF as an inadequate primary endpoint, and refused to bless a replacement mid-trial, breaking both legs of the catalyst-trade thesis; if you bought the March squeeze, the thesis broke today.
  10. Avoid UPDATE: Longeveron (LGVN) - The ATM Trap Snaps Shut The Q1 10-Q reveals the ATM is frozen below $0.80 and the stock is already through that floor, narrowing financing optionality further while the Nasdaq September deadline now sits inside the post-data window; the May 8 downgrade thesis is intact and modestly hardened.
  11. Avoid UPDATE: Longeveron (LGVN) - Four Weeks of Oxygen Left Q2 shows $10.1M cash against a $5.7M quarterly burn with the ATM producing only $42K all quarter, the Nasdaq deadline sits nine days after the September data window, and the second $15M tranche milestone may be unreachable by its own terms; the binary event is closer with fewer chips.
  12. Avoid UPDATE: Longeveron (LGVN) - They Spent the Bullet Before the Data The 1-for-10 reverse split protects the Nasdaq listing ahead of the September readout but spends the only mechanical fix before the binary event, opening a one-year re-breach trapdoor where a miss triggers immediate delisting with no cure period.
  13. Avoid UPDATE: Longeveron (LGVN) - The Envelope Opened and It Was Empty ELPIS II missed its primary endpoint outright (p=0.8336) and the sponsor composite also failed in ITT; the 2027 BLA path, second $15M tranche, and PRV upside are all gone, leaving a strategic-review shell with roughly one quarter of cash and a $1.00 delisting trapdoor.
  14. Avoid UPDATE: Longeveron (LGVN) - The Envelope Gets Re-Opened A pre-specified MACE secondary hit p=0.043 (8 vs 1 events) and earned an AHA late-breaker slot, providing the best marketing material for the strategic review, but nine events after a missed primary on a company with roughly one quarter of cash and a $1.00 delisting trapdoor does not justify re-entry.
  15. Avoid UPDATE: Longeveron (LGVN) - No Call, Open ATM Q3 shows $7.2M cash with runway stretched to Q1 2027 partly on unpaid bills, the ATM is now unlocked with $9.3M capacity against a ~$10M market cap, a formal sale process is underway with a disclosure blackout, and common holders rank last in any transaction outcome.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (2 quotes from 2 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (46)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jun 4, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

15 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)